Loncastuximab tesirine
Zynlonta · Antibody-drug conjugate (CD19/PBD)
Capillary-leak-type edema, effusions and AKI.
Trifunctional bispecific (EpCAM×CD3)
Removab · Catux
Trifunctional bispecific (EpCAM×CD3) · approved 2009 · 4 citations
Describes how this page is sourced, not how dangerous the drug is. Thinly sourced means fewer of the sourcing signals are met — not that the agent is kidney-safe. A rule-based summary, not a formal certainty appraisal.
An intraperitoneal trifunctional antibody whose cytokine-release storm threatens the kidney prerenally.
Atlas fields gathered in one place, each linked to the section with its full text and sources. Educational, not medical advice.
Signature lesion
No characteristic intrinsic nephrotoxicity. The dominant treatment-related toxicity is cytokine-release-related (pyrexia, nausea, vomiting, chills, fatigue) plus intraperitoneal-administration effects (abdominal pain); transient transaminase rises and lymphopenia are common but usually clinically minor. Cytokine release with fever, GI losses, and large-volume ascites/paracentesis creates a setting for prerenal/hemodynamic AKI rather than a direct renal lesion. Drug-specific renal incidence is not quantified.Source: Berek et al., Int J Gynecol Cancer 2014 (phase II); Frampton, Drugs 2012 (pivotal II/III review)
Cytokine-release symptoms within hours of each intraperitoneal infusion; prerenal AKI follows the inflammatory/volume insult.
Distilled from: “Cytokine-release symptoms within hours of each intraperitoneal infusion; any prerenal AKI follows the inflammatory/volume insult.”
This agent's kidney lesions ordered by prominence — the #1 signature lesion first, then secondary and rare patterns. Cited incidence is shown where a citable figure exists; otherwise the tier stands qualitatively.
Renal hypoperfusion from capillary leak and cytokine storm — IL-2 and CAR-T cytokine release syndrome.
Renal electrolyte derangement — magnesium/potassium/calcium wasting (cisplatin, anti-EGFR antibodies) or retention (FGFR-inhibitor hyperphosphatemia, tumor-lysis hyperkalemia/hyperphosphatemia).
Trifunctional rat/mouse hybrid bispecific antibody binding EpCAM on tumor cells and CD3 on T cells, while its intact Fc region engages Fc-gamma-receptor-positive accessory immune cells (macrophages, NK cells, dendritic cells). This tri-cell complex drives potent T-cell- and accessory-cell-mediated tumor killing. Administered intraperitoneally for malignant ascites due to EpCAM-positive tumors.
Vasculature / Endothelium
Glomerular & peritubular capillaries
Class-level context for the major non-renal toxicities of the Trifunctional bispecific (EpCAM×CD3) class.
Immune / Infusion
CRS, infusion reactions, irAEs, anaphylaxis
Neurologic
Neuropathy, encephalopathy, ICANS, PRES
Hematologic
Cytopenias, thrombosis, TMA
3 primary references — trials, cohorts, mechanism, and reviews. Single-patient case reports are listed separately below, graded by strength. Citation metadata via PubMed / NLM.
Primary (non–case-report) references per year — a proxy for how actively the agent's renal literature is accruing. Recent years are highlighted. Reflects curation depth, not a systematic bibliometric count.
Single-patient and small-series reports, graded by evidentiary strength — A Strong (biopsy-proven plus a series and/or positive rechallenge), B Moderate, and C Limited (a single clinically-diagnosed case). Strongest first. Grades are inferred automatically from each report's abstract and journal — a heuristic ranking aid, not a formal quality appraisal.
Everything below is FAERS — adverse events someone chose to report, about 3 of them for this agent. Nobody counts the patients who were fine, so none of these numbers is an incidence, a risk, or a rate: they describe what gets reported, shaped by a drug's fame, its indication, and who was watching. How these numbers work.
3 total FAERS reports is below the 50 this atlas requires before quoting an odds ratio, so report counts are shown instead of RORs and none of these counts as a signal. A phenotype missing below was queried and never cleared even the nominal CI bar, except Prerenal / Hemodynamic AKI, Pseudo-AKI, Renal Cysts, Chronic Interstitial Nephropathy — outside the clinician-reviewed MedDRA term map, never queried — and ATN and AIN, queried but biopsy-bound: real cases are filed as generic “acute kidney injury”, so their absence is not a negative. As of 2026-11-15.
What reporting says about this profile's documented lesions
3 reports is below the 50 this atlas requires before quoting a percentage, so the counts are shown instead of shares.
Counted by the report's active-substance field, which FAERS fills almost only on reports received from 2013 on, so these figures describe reports since then, not the agent's whole history.
Reported with a death outcome
too few reports to express as a share
Reported with hospitalization
too few reports to express as a share
Reports per year
Reports received per year, 2015–2026 · most recent year is partial.
Bars rank systems by summed reaction-term mentions (a report counts once per term it names) — an ordinal “more vs less reported” cue, not a tally of distinct reports. Renal & urinary first. As of 2026-11-15.
Each recommendation below is this atlas's faithful summary of the source, not a quotation from it — follow the PubMed link for the wording the society published. Summaries may be superseded; consult the current full text and individualize to the patient.
General onco-nephrology references
Where Catumaxomab sits in nephrotoxicity space — each dot is an anti-cancer agent, positioned so neighbors share a kidney-injury phenotype. Its 6 closest are filled and lead to a numbered marker, matching the numbered cards below.
Zynlonta · Antibody-drug conjugate (CD19/PBD)
Capillary-leak-type edema, effusions and AKI.
Truqap · AKT inhibitor
2023 breast-cancer AKT inhibitor; AKI with diarrhea/hyperglycemia.
Tecelra · MAGE-A4 TCR-T cell therapy
First TCR-T cell therapy for a solid tumor; CRS-associated hemodynamic AKI.
Komzifti · Menin inhibitor
2025 NPM1-mutated AML menin inhibitor; differentiation syndrome and tumor lysis.
Ayvakit · KIT / PDGFRA inhibitor
Edema, intracranial bleeding and cognitive effects.
Vanflyta · FLT3 inhibitor
2023 AML FLT3 inhibitor; tumor lysis and QT.
Nearest agents by kidney-injury phenotype (shared injuries, nephron target, severity, class) — a similarity approximation, not a claim of shared drug identity or mechanism.
Same-class agents ordered by their documented kidney-injury profile — atlas severity, an acute-kidney-injury FAERS signal, and how many injury types each is documented to cause. Agents nearer the top carry the lighter documented renal profile. Agents sharing a number are tied on all three. An agent marked FAERS n/a has too few reports to test, so its place rests on severity and injury breadth alone.
A comparison of documented kidney-injury data within one drug class — not a substitution recommendation. Efficacy, indication, and non-renal toxicity differ between these agents and are out of scope here. Educational only, not medical advice.